Robinhood gives you the tools you need to put your money in motion. You can buy or sell Biogen and other ETFs, options, and stocks.
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of severe plaque psoriasis.
52 Week High
52 Week Low
Biogen sales face pressure from slow uptake of Alzhiemer's drug
Aduhelm, Biogen's controversial recently approved drug for early Alzheimer's disease, is seen at Butler Hospital, one of the clinical research sites in Providen
Expert Ratings For Biogen - Biogen Idec
Over the past 3 months, 13 analysts have published their opinion on Biogen (NASDAQ:BIIB) stock. These analysts are typically employed by large Wall Street banks
$4.14 per share
Available Oct 20, Pre-Market
Biogen Stock Drops as ALS Trial Fails. Ionis Is Getting Hit Even Harder.
MarketWatch Shares of Biogen were down 0.6% in premarket trading on Monday, the day after the company said an experimental amyotrophic lateral sclerosis (ALS)
Ionis Pharma Shares Drop 12% After Tofersen Study Misses Primary Endpoint
By Chris Wack Ionis Pharmaceuticals Inc. shares fell 12% to $30.90 after the company said a study for tofersen missed its primary endpoint. The company said i
Biogen says ALS drug did not meet primary endpoint in Phase 3 clinical trial
Shares of Biogen BIIB, -1.43% were down 0.6% in premarket trading on Monday, the day after the company said an experimental amyotrophic lateral sclerosis (ALS)
Fox BusinessOct 17
In quiet debut, Alzheimer’s drug finds questions, skepticism
The first new Alzheimer’s treatment in more than 20 years was hailed as a breakthrough when regulators approved it more than four months ago, but its rollout ha